Norwich Pharma Services

Alvotech Appoints Interim Chief Quality Officer

Retrieved on: 
Thursday, February 29, 2024

REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer.

Key Points: 
  • REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer.
  • Christina Siniscalchi has for over ten years served in senior quality positions for Alvogen and its manufacturing site in Norwich, NY, most recently as Alvogen’s Chief Quality Officer.
  • “We thank Sandra for her valuable contribution to Alvotech, as she successfully steered our quality team through the recent FDA facility inspection, which now has led to the approval of our interchangeable high-concentration biosimilar to Humira in the U.S.,” said Robert Wessman, Chairman and CEO of Alvotech.
  • Continuous improvement, quality, and compliance, is at the heart of everything we do.”
    Christina Siniscalchi has 25 years of experience in the U.S. pharmaceuticals industry.

Oncocyte Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023.

Key Points: 
  • IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023.
  • Josh Riggs, CEO of Oncocyte, commented, “Oncocyte received a positive coverage decision from CMS during the third quarter for the Company's innovative VitaGraft Kidney.
  • For Oncocyte’s complete financial results for the third quarter ended September 30, 2023, see the Company’s Quarterly Form 10-Q to be filed with the Securities and Exchange Commission on November 9, 2023.
  • Oncocyte will host a conference call to discuss the third quarter 2023 financial results prior to market open on Thursday, November 9, 2023 at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.

Crosstree Continues Rapid Expansion with First Chief Marketing and Growth Officer and Three New Directors

Retrieved on: 
Tuesday, October 24, 2023

TAMPA, Fla., Oct. 24, 2023 /PRNewswire/ -- Crosstree, the global leader in health sciences M&A, is thrilled to announce the appointment of Sandra G. Callahan to the position of chief marketing and growth officer, the first in the firm's history, and the addition of three new directors. These hires mark a turning point in the firm's trajectory and further solidify Crosstree's position as the largest strategic advisory team exclusively dedicated to Health Sciences.

Key Points: 
  • TAMPA, Fla., Oct. 24, 2023 /PRNewswire/ -- Crosstree, the global leader in health sciences M&A, is thrilled to announce the appointment of Sandra G. Callahan to the position of chief marketing and growth officer, the first in the firm's history, and the addition of three new directors.
  • These hires mark a turning point in the firm's trajectory and further solidify Crosstree's position as the largest strategic advisory team exclusively dedicated to Health Sciences.
  • Sandra's expertise in executing high-growth business strategies while centered on delivering value to clients, positions Crosstree to achieve its rapid growth targets.
  • Sandra added, "I'm thrilled to be joining such a distinguished firm at an exciting point in their growth story.

REALM IDx Launches REALM Pharma Services to Improve Drug Development and Research

Retrieved on: 
Thursday, June 1, 2023

REALM IDx announced today the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners.

Key Points: 
  • REALM IDx announced today the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners.
  • Through a strategic integration, REALM Pharma Services brings together the research arms of subsidiaries, Ambry Genetics and Invicro, to offer cutting-edge genomics, traditional and molecular pathology, and advanced imaging and spatial biology.
  • “In supporting our biopharma partners, we see ourselves as a powerful connecting force,” said Jonathan Usuaka, PhD, Chief Strategy and Informatics Officer for REALM IDx.
  • Additional information about REALM Pharma Services may be found on REALM’s website .

Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region

Retrieved on: 
Friday, May 19, 2023

“Thermo Fisher Scientific's fill-finish manufacturing facility will enable end-to-end vaccine manufacturing to be carried out in Singapore.

Key Points: 
  • “Thermo Fisher Scientific's fill-finish manufacturing facility will enable end-to-end vaccine manufacturing to be carried out in Singapore.
  • This strategic investment in Singapore complements new research capabilities at Thermo Fisher Scientific's Customer Experience Center and Bioprocess Design Center, two other operational lab facilities that showcase the latest bioprocessing, life science, and analytical technologies.
  • Together, these sites allow Thermo Fisher to better enable customers to accelerate their research, as well as develop and commercialize new medicines and vaccines in the Asia-Pacific market.
  • In total, over 2,000 company employees are contributing to Singapore’s evolution as a biomedical hub in the Asia-Pacific region.

Alcami Appoints Laurent Boer as General Manager of Biostorage and Pharmaceutical Support Services.

Retrieved on: 
Tuesday, May 16, 2023

WILMINGTON, N.C. , May 16, 2023 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), announced today the appointment of Laurent Boer to the newly created position of General Manager, Biostorage and Pharma Services.

Key Points: 
  • WILMINGTON, N.C. , May 16, 2023 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), announced today the appointment of Laurent Boer to the newly created position of General Manager, Biostorage and Pharma Services.
  • Before joining Alcami, Laurent was Vice President & General Manager at Resilience's biomanufacturing site in Allston, Massachusetts.
  • "I am thrilled and honored to join Alcami," commented Laurent Boer, General Manager of Biostorage and Pharma Services at Alcami.
  • This important appointment came on the heel of Alcami's recent biostorage expansion that added more secure and reliable cGMP biostorage in New Hampshire and Massachusetts.

Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023

SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2023.
  • clonoSEQ test volume increased 57% to 12,079 tests delivered in the first quarter 2023, compared to the first quarter of prior year.
  • Immune Medicine generated $16.2 million in revenue during the first quarter 2023 from two distinct areas (Pharma Services and Drug Discovery), representing 43% of total first quarter revenue.
  • Adaptive Biotechnologies will host a conference call to discuss its first quarter 2023 financial results after market close on Wednesday, May 3, 2023 at 4:30 PM Eastern Time.

Dennis Huang of Ultragenyx Named to MassBio’s Board of Directors

Retrieved on: 
Friday, April 28, 2023

As a member of the board, Huang will support MassBio’s mission to advance Massachusetts’ leadership in the life sciences, to grow the industry, add value to the healthcare system and improve patient lives.

Key Points: 
  • As a member of the board, Huang will support MassBio’s mission to advance Massachusetts’ leadership in the life sciences, to grow the industry, add value to the healthcare system and improve patient lives.
  • “I am honored to join the board at MassBio, a leader in and powerful partner to this globally recognized ecosystem of life-science innovation,” Huang said.
  • “MassBio and Ultragenyx share a commitment to supporting research and policies that advance innovation.
  • Prior to joining Ultragenyx, Huang held senior leadership roles at InterMune Inc., Allergan, Inc., Novartis AG (formerly Chiron, Inc), Genentech, Inc., and Synergen (currently Amgen).

Flagship Biosciences appoints Gina Wallar, Ph.D., MPH as new Chief Commercial Officer

Retrieved on: 
Thursday, March 9, 2023

BROOMFIELD, Colo., March 9, 2023 /PRNewswire-PRWeb/ -- Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the appointment of Gina Wallar, Ph.D., MPH as their new Chief Commercial Officer. Gina is an accomplished business executive in the diagnostics and pharma services industry with 20 years' experience leading international sales teams, managing people, and spearheading business development from a financial perspective.

Key Points: 
  • , a leader in spatial biology and biomarker analytics services, announced the appointment of Gina Wallar, Ph.D. , MPH as their new Chief Commercial Officer.
  • Gina brings over 20 years of experience in commercial, operational, and scientific expertise, having held leadership positions at several large, commercial organizations," said CEO Trevor Johnson.
  • Prior to joining Flagship Biosciences, Dr. Wallar acted as Senior Vice President for Fulgent Genetics where she led their sales and business development efforts.
  • "This is a remarkable time to join the Flagship Biosciences team," said Gina.

Elektrofi Announces Collaboration with Thermo Fisher Scientific to Strengthen Manufacturing Capabilities for Future Clinical Trials

Retrieved on: 
Tuesday, February 7, 2023

Based on strong preclinical validation and partner interest, the company expects to initiate multiple clinical trials in 2024.

Key Points: 
  • Based on strong preclinical validation and partner interest, the company expects to initiate multiple clinical trials in 2024.
  • “To successfully initiate clinical development, we need to establish certified cGMP manufacturing capabilities.
  • “Our expertise in drug development and manufacturing will help Elektrofi pioneer a significant advance in how medicine is introduced into patients,” said Leon Wyszkowski, President, Commercial Operations, Pharma Services for Thermo Fisher Scientific.
  • “We deeply appreciate their confidence in us and look forward to the clinical research progress we will make together."